Victoria Palafox-Sanchez

Victoria Palafox-Sanchez

Auto-generated profile, based on publicly available information

Victoria Palafox-Sanchez


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2026 in Research Square
Verified
Preprint
Open access
PDF file
HVHector Chapoy Villanueva
Hector Chapoy Villanueva
GGGerardo García-Rivas
Gerardo García-Rivas
LMLuis Luevano Martinez
Luis Luevano Martinez
VPVictoria Palafox-Sanchez
Victoria Palafox-Sanchez
EGEmanuel Adrián Guajardo-Correa
Emanuel Adrián Guajardo-Correa
Norma A BobadillaNorma A Bobadilla
Norma A Bobadilla
Cardiorenal syndrome (CRS) is characterized by bidirectional heart–kidney dysfunction in which oxidative stress, inflammation, and mitochondrial dysfunction drive progressive kidney injury, but the role of mitochondrial calcium (Ca²⁺) handling through the mitochondrial calcium uniporter (MCU) complex remains unclear. Here we show, in a mouse model of CRS induced by angiotensin II and L-NAME in male mice (C57BL/6), that renal mitochondria exhibit increased MCU expression, reduced Ca²⁺ retention capacity, and greater susceptibility to Ca²⁺-induced permeability transition, alongside impaired respiration, reduced PGC-1α and TFAM expression, oxidative stress, and inflammatory activation. Cannabidiol (CBD) attenuates renal dysfunction and structural injury, restores mitochondrial respiratory capacity and complex I activity, normalizes MCU expression, and partially improves mitochondrial Ca²⁺ handling, independently of blood pressure reduction. These findings identify MCU-dependent mitochondrial Ca²⁺ dysregulation as a candidate mechanism linking mitochondrial dysfunction to renal injury in CRS, and a potential target for CBD’s nephroprotective effects.